Table 3. Results of follow-up of TL-seropositive subjects.
Year | 2015 | 2017 | 2018 | 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Health district | PEx | S | T | PEx | S | T | PEx | S | T | PEx | S | T |
Bouaflé | 13 | 10 | 0 | 18 | 13 | 1 | 16 | 9 | 0 | 17 | 9 | 0 |
Sinfra | 0 | 0 | 0 | 9 | 7 | 0 | 2 | 1 | 0 | 13 | 8 | 1 |
Vavoua | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Daloa | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 1 | 0 | 2 | 1 | 0 |
Total | 15 | 12 | 0 | 29 | 22 | 1 | 20 | 11 | 0 | 33 | 18 | 1 |
PEx = population examined; S = number of TL-seropositive subjects; T = number of confirmed gHAT cases